Abstract: Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

Abstract: The present invention is related to patient interfaces, such as nasal masks (2), particularly though not solely for use in providing continuous positive airway pressure therapy or positive pressure ventilation to patients suffering from obstructive sleep apnoea. In a first form the invention is a patient interface that has securement means (601) releasably attaching the interface to headstraps wherein the securement means (601) is slidably engaged with the patient interface, In a second form of the invention the mask headgear is formed of a plurality of straps (701, 702) where at least one of the plurality of straps is slidably engaged with another of the plurality of straps. In a further form the patient interface may be provided with vertically adjustable engaging means (802) that engage the patient interface with the headgear straps.

Abstract: The present invention is a mask for the delivery of gases to a patient. The mask has a hollow body and a cushion that seals against the user's face. The cushion is comprised of an inner resilient cushion and an outer flexible sheath. The cushion preferably extends below the patient's chin when in use.

Abstract: Imidazole compounds of Formula (I): (where A, B, R11, R12, W, X, Y and Z are as defined herein) wherein the imidazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, which are MgluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases, and pharmaceutical compositions and methods of treating these diseases.

Abstract: Novel pyrazole compounds such as compounds of the formula (I): (where A, A1, A2, B, R11, W, X, Y and Z are as defined herein) in which the pyrazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, obesity, drug addiction, drug abuse, drug withdrawal and other diseases.

Abstract: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

Abstract: Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.

Abstract: A computerized system and method of building a system of test components for an orderable healthcare procedure is provided. An orderable healthcare procedure is received and associated with a discrete ontology concept. An ontology is traversed for the discrete ontology concept to identify test components related to the discrete ontology concept. The test components related to the discrete ontology concept are identified.

Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.

Abstract: A data processing apparatus comprises at least one source processor core (110), at least one destination processor core (120), a message handler (130) and a bus arrangement (150) providing a data communication path between the source core, the destination core and the message handler. The message handler (130) has plurality of message-handling modules (132-1 to 132-3). At least one of the message-handling modules (132-1 to 132-3) is programmable to enable exclusive control by a specified source processor core.

Abstract: Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

Abstract: The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating ?L?2 adhesion mediated conditions in a mammal.

Abstract: A data processing apparatus comprises at least one source processor core (110), at least two destination processor cores (120), a message handler (130) and a bus arrangement (150) providing a data communication path between the source core, the destination cores and the message handler. The message handler (130) has plurality of message-handling modules (132-1 to 132-3). At least one of the message-handling modules has a message receipt indicator that is modifiable by each of the destination processor cores to indicate that a message has been received at its destination. This message-handling module also has a transmission completion detector operable to detect, in dependence upon a message receipt indicator value that a message has been received by all of the at least two destination processor cores and to initiate transmission of an acknowledgement signal to the source processor core.

Abstract: The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating ?L?2 adhesion mediated conditions in a mammal.

Abstract: Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

Abstract: A mouthpiece for oral delivery for oral delivery of CPAP treatment has a vestibular shield for location between the teeth and lips/cheeks of a wearer. The vestibular shield is formed from a very supple material and is dimensioned to extend laterally into the buccal vestibule and vertically to overlap the gums. A gases pathway is provided through the vestibular shield and may include a hard plastic insert through the shield. A connection for connecting the mouthpiece to a breathing circuit is provided which reduces the transfer of forces caused by movement therebetween.

Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.

Abstract: A data processing apparatus controls cross-triggering of diagnostic processes on a plurality of processing devices. The data processing apparatus comprises a routing module having a plurality of broadcast channels, one or more of the broadcast channels being operable to indicate the occurrence of a diagnostic event on one or more of the plurality of processing devices. The data processing apparatus also comprises an mapping module associated with a corresponding processing device. The interface module programmably asserts diagnostic event signals from the associated processing device to one or more of the plurality of broadcast channels and programmably retrieves diagnostic events signals from processing devices other than the associated processing device from one or more of the plurality of broadcast channels. The retrieved diagnostic event data is used to facilitate triggering of a diagnostic process on the associated processing device in dependence upon said retrieved diagnostic event data.

Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.

Abstract: The present invention is related to patient interfaces, such as nasal masks (2), particularly though not solely for use in providing continuous positive airway pressure therapy or positive pressure ventilation to patients suffering from obstructive sleep apnoea. In a first form the invention is a patient interface that has securement means (601) releasably attaching the interface to headstraps wherein the securement means (601) is slidably engaged with the patient interface. In a second form of the invention the mask headgear is formed of a plurality of straps (701, 702) where at least one of the plurality of straps is slidably engaged with another of the plurality of straps. In a further form the patient interface may be provided with vertically adjustable engaging means (802) that engage the patient interface with the headgear straps.